Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR Stock Report

Market Cap: US$7.6m

Citius Pharmaceuticals Management

Management criteria checks 2/4

Citius Pharmaceuticals' CEO is Leonard Mazur, appointed in Mar 2016, has a tenure of 9.17 years. total yearly compensation is $3.52M, comprised of 13.5% salary and 86.5% bonuses, including company stock and options. directly owns 6.84% of the company’s shares, worth $517.20K. The average tenure of the management team and the board of directors is 4.3 years and 9 years respectively.

Key information

Leonard Mazur

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage13.49%
CEO tenure9.2yrs
CEO ownership6.8%
Management average tenure4.3yrs
Board average tenure9yrs

Recent management updates

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01
Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25
Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05
Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Jul 05

Critical Care Biopharma - Citius Pharmaceuticals

Apr 13

Citius: 2022 Is A Year Of Catalysts

Mar 28

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28
Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Leonard Mazur's remuneration changed compared to Citius Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$43m

Dec 31 2024n/an/a

-US$41m

Sep 30 2024US$4mUS$475k

-US$40m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023n/an/a

-US$39m

Sep 30 2023US$2mUS$475k

-US$34m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$28m

Sep 30 2022US$1mUS$400k

-US$34m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021n/an/a

-US$26m

Sep 30 2021US$788kUS$348k

-US$25m

Jun 30 2021n/an/a

-US$24m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020n/an/a

-US$21m

Sep 30 2020US$550kUS$250k

-US$18m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019n/an/a

-US$16m

Sep 30 2019US$473kUS$250k

-US$16m

Jun 30 2019n/an/a

-US$15m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018n/an/a

-US$13m

Sep 30 2018US$398kUS$250k

-US$13m

Compensation vs Market: Leonard's total compensation ($USD3.52M) is above average for companies of similar size in the US market ($USD647.92K).

Compensation vs Earnings: Leonard's compensation has increased whilst the company is unprofitable.

CEO

Leonard Mazur (79 yo)

9.2yrs
Tenure
US$3,521,268
Compensation

Mr. Leonard L. Mazur is Chairman, Chief Executive Officer & President of Citius Oncology, Inc. from August 12, 2024. He has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01, 2022....

Leadership Team

NamePositionTenureCompensationOwnership
Leonard Mazur
Co-Founder9.2yrsUS$3.52m6.84%
$ 517.2k
Myron Holubiak
Co-Founder & Executive Vice Chairman9.6yrsUS$2.20m0.81%
$ 61.4k
Jaime Bartushak
Chief Business Officer & CFO7.5yrsUS$1.73m0.025%
$ 1.9k
Gary Talarico
Executive Vice President of Operations9.2yrsno datano data
Ilanit Allen
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Alan Lader
Senior VP and Head of Clinical Operations & Quality Assurance3.3yrsno datano data
Myron Czuczman
Executive VP & Chief Medical Officer4.8yrsUS$1.17m0%
$ 0
Dhananjay Wadekar
Senior Vice President of Business Strategy4.3yrsno datano data
Kelly Creighton
Executive Vice President of Chemistry3.5yrsno datano data
Nikolas Burlew
Executive Vice President of Quality Assurance2.3yrsno datano data
Catherine Kessler
Executive Vice President of Regulatory Affairs1.7yrsno datano data
4.3yrs
Average Tenure
69.5yo
Average Age

Experienced Management: CTXR's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Leonard Mazur
Co-Founder10.7yrsUS$3.52m6.84%
$ 517.2k
Myron Holubiak
Co-Founder & Executive Vice Chairman9.6yrsUS$2.20m0.81%
$ 61.4k
Dennis McGrath
Independent Director2.3yrsUS$306.27k0%
$ 0
Michael Matthay
ARDS Scientific Advisory Board Memberno datano datano data
Suren Dutia
Independent Director9.6yrsUS$293.56k0%
$ 0
Carol Webb
Independent Director9.2yrsUS$270.73k0.0048%
$ 363.9
Eugene Holuka
Independent Director8.9yrsUS$274.06k0.00097%
$ 73.4
Issam Raad
Chairman of Scientific Advisory Boardno datano datano data
Mark Rupp
Member of Scientific Advisory Boardno datano datano data
Leonard Mermel
Member of Scientific Advisory Board6.8yrsno datano data
John Laffey
ARDS Scientific Advisory Board Member3.9yrsno datano data
Lorraine Ware
ARDS Scientific Advisory Board Memberno datano datano data
9.0yrs
Average Tenure
77yo
Average Age

Experienced Board: CTXR's board of directors are considered experienced (9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 21:44
End of Day Share Price 2025/05/20 00:00
Earnings2025/03/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Citius Pharmaceuticals, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Jason KolbertH.C. Wainwright & Co.
Vernon BernardinoH.C. Wainwright & Co.